S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Forecast, Price & News

$0.21
0.00 (0.00%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.20
$0.21
50-Day Range
$0.20
$0.59
52-Week Range
$2.11
$17.50
Volume
973 shs
Average Volume
2.44 million shs
Market Capitalization
$840,795.13
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CGIX stock logo

About Cancer Genetics (NASDAQ:CGIX) Stock

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Cancer
Hundreds call helpline over Orkney cancer gene
StockNews.com Begins Coverage on Cancer Genetics (NASDAQ:CGIX)
See More Headlines

CGIX Price History

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CGIX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.33 million

Miscellaneous

Free Float
N/A
Market Cap
$831,297.50
Optionable
Not Optionable
Beta
2.72

Key Executives

  • John A. Roberts
    President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence
    Chief Operating & Financial Officer
  • Robert T. Fremeau
    Chief Scientific Officer
  • Ping Yeh
    Director & Chief Innovation Officer
  • Ralf Brandt
    President-Discovery & Early Development Services













CGIX Stock - Frequently Asked Questions

How have CGIX shares performed in 2023?

Cancer Genetics' stock was trading at $0.7025 on January 1st, 2023. Since then, CGIX shares have decreased by 71.0% and is now trading at $0.2035.
View the best growth stocks for 2023 here
.

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?
What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $0.20.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $831,297.50 and generates $6.33 million in revenue each year.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for the company is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -